Andrew Timothy Ng, Tyler Steve, Kevin T Jamouss, Abdul Arham, Sarah Kawtharani, Hazem I Assi
{"title":"The challenges and clinical landscape of glioblastoma immunotherapy.","authors":"Andrew Timothy Ng, Tyler Steve, Kevin T Jamouss, Abdul Arham, Sarah Kawtharani, Hazem I Assi","doi":"10.1080/20450907.2024.2415878","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma is associated with a dismal prognosis with the standard of care involving surgery, radiation therapy and temozolomide chemotherapy. This review investigates the features that make glioblastoma difficult to treat and the results of glioblastoma immunotherapy clinical trials so far. There have been over a hundred clinical trials involving immunotherapy in glioblastoma. We report the survival-related outcomes of every Phase III glioblastoma immunotherapy trial with online published results we could find at the time of writing. To date, the DCVax-L vaccine is the only immunotherapy shown to have statistically significant increased median survival compared with standard-of-care in a Phase III trial: 19.3 months versus 16.5 months. However, this trial used an external control group to compare with the intervention which limits its quality of evidence. In conclusion, glioblastoma immunotherapy requires further investigation to determine its significance in improving disease survival.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2415878"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20450907.2024.2415878","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Glioblastoma is associated with a dismal prognosis with the standard of care involving surgery, radiation therapy and temozolomide chemotherapy. This review investigates the features that make glioblastoma difficult to treat and the results of glioblastoma immunotherapy clinical trials so far. There have been over a hundred clinical trials involving immunotherapy in glioblastoma. We report the survival-related outcomes of every Phase III glioblastoma immunotherapy trial with online published results we could find at the time of writing. To date, the DCVax-L vaccine is the only immunotherapy shown to have statistically significant increased median survival compared with standard-of-care in a Phase III trial: 19.3 months versus 16.5 months. However, this trial used an external control group to compare with the intervention which limits its quality of evidence. In conclusion, glioblastoma immunotherapy requires further investigation to determine its significance in improving disease survival.
胶质母细胞瘤的预后很差,标准治疗包括手术、放疗和替莫唑胺化疗。本综述探讨了胶质母细胞瘤难以治疗的特点,以及迄今为止胶质母细胞瘤免疫疗法临床试验的结果。目前已有百余项胶质母细胞瘤免疫疗法临床试验。我们报告了在撰写本报告时所能找到的、已在线公布结果的每项胶质母细胞瘤免疫疗法 III 期临床试验的生存相关结果。迄今为止,在III期试验中,DCVax-L疫苗是唯一一种与标准疗法相比中位生存期有显著统计学增长的免疫疗法:19.3个月对16.5个月。不过,该试验使用了外部对照组与干预组进行比较,这限制了其证据质量。总之,胶质母细胞瘤免疫疗法需要进一步研究,以确定其在改善疾病生存方面的意义。